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Objectives
Pharmaceutical companies use Phase II trial results to
make decisions about proceeding to Phase III. We will
show how a meta-analysis of results from multiple
Phase II trials is informative toward this decision.
Methods
We consider a meta-analysis of nine randomised Phase
II trials comparing the efficacy of two therapies for
acute myocardial infarction. Results for four outcomes
were collected: intracranial haemorrhage, stroke, rein-
farction and total mortality.
We apply univariate and multivariate random-effects
meta-analysis methods, and use the obtained summary
results to derive 95% prediction intervals, which give
the predicted treatment effects for the four outcomes
in a future trial. The multivariate approach jointly
synthesizes all outcomes whilst accounting for their
correlation. The methods are applicable in both fre-
quentist and Bayesian frameworks. Predictions calcu-
lated are compared to results from subsequent Phase
III trials.
Results
The meta-analyses of Phase II trials show that the new
treatment is promising for most outcomes. For example,
the probability that the odds of stroke will be reduced by
>10% in a future trial is 0.67. Importantly, the prediction
intervals include the treatment effects that were seen in
subsequent Phase III trials. These Phase III results have
previously been described as ‘contradictory’ to the Phase
II results, but our prediction intervals reveal this is not
the case.
Conclusions
The potential results of a Phase III trial can be informed
by 95% prediction intervals derived from a Phase II
meta-analysis. Such predictions could help pharmaceuti-
cal companies and funding bodies to prioritise interven-
tions for Phase III evaluation.
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